Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 13
SAN DIEGO , Dec. 22, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 , at
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Dec. 18, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on December 15, 2020 , the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 141,975 shares of its common
View HTML
Toggle Summary Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference
- Data selected for late-breaker oral presentation on December 14 - Novel mechanism of action evaluated in moderate-to-severe atopic dermatitis (AD) - Significant unmet need exists for a safe, once-daily, oral therapy in AD SAN DIEGO , Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
View HTML
Toggle Summary Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial
- Evaluating 2 mg etrasimod in study participants with moderately to severely active ulcerative colitis (UC) - Topline data from ELEVATE UC 12 and UC 52 trials on track for Q1 2022 - Due to the high number of participants currently in screening queue, screening to continue for an additional three
View HTML
Toggle Summary Arena Pharmaceuticals Announces R&D Leadership Transition
Paul D. Streck , M.D., Appointed as Senior Vice President, Clinical Development and Chief Medical Officer, Bringing Successful Development and Launch Experience Across Multiple Therapeutic Indications SAN DIEGO --(BUSINESS WIRE)--Nov. 30, 2020-- Arena Pharmaceuticals, Inc.
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the Evercore ISI HealthCONx Conference on December 1
SAN DIEGO , Nov. 24, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Tuesday,
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Nov. 19, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on November 15, 2020 , the Compensation Committee of its Board of Directors granted to 13 new employees inducement stock options to purchase an aggregate of 96,025 shares of its common stock
View HTML
Toggle Summary Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial
- Etrasimod 2 mg in the primary analysis achieved statistical significance of the registrational endpoint vIGA at week 12   - Etrasimod 2 mg in the primary analysis demonstrated statistical significance in percent change in EASI, EASI-75, and pruritis at week 4   - Etrasimod did not meet the Ph 2b
View HTML
Toggle Summary Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company
- Longboard Pharmaceuticals (formerly Arena Neuroscience) is an Arena-founded independent company focused on advancing promising investigational therapies for rare neurological diseases   - Longboard's investor syndicate includes Farallon Capital, Cormorant Asset Management, HBM Healthcare
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Oct. 20, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on October 15, 2020 , the Compensation Committee of its Board of Directors granted to seven new employees inducement stock options to purchase an aggregate of 66,475 shares of its common stock
View HTML